Gap Inc vs Globus Medical Inc. Class A Common Stock — how do they compare? Gap Inc trades at $22.66 (market cap $8.02B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Globus Medical Inc. Class A Common Stock is the larger of the two by market cap, and Gap Inc pays a 3.07% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gap Inc for 37 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| GAP | GMED | |
|---|---|---|
Market Cap | $8.02B | $10.25B |
Volume | 4,496,595 | 1,108,124 |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $96.82 |
52-Week Low | $18.35 | $58.33 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $11.25B | $9.76B |
Dividend Yield | 3.07% | — |
Signals from Pluang's Aura AI — not financial advice
Gap trades at $22.67, down 0.48% on the day, with a bullish technical signal supported by strong moving averages. The company shows improving fundamentals with revenue growth to $15.09B in 2025 and net income margin expanding to 8.14%. Recent strategic moves include music partnerships and board appointments, while analyst consensus targets $25.67 with 31% buy ratings.
The outlook remains positive with projected 2026 revenue of $15.3B and net income of $1.2B, though risks include Old Navy's sales decline and competitive pressures. Valuation appears attractive with P/E of 6.88 and P/S of 0.56, suggesting potential upside to consensus targets if execution continues.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →